ArticleAdvances in ophthalmology practice and research
RUNX1 promotes pathological retinal angiogenesis through von Willebrand factor.
Article in Advances in ophthalmology practice and research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Runt-related transcription factor 1 (RUNX1) is a key transcriptional regulator for angiogenesis, and its pharmacological inhibition attenuates retinal pathological angiogenesis. However, the functional mechanisms by which RUNX1 promotes angiogenesis, especially at the protein level, remain poorly understood. Methods: Using an oxygen-induced retinopathy (OIR) model and a RUNX1 inhibition (Ro5-3335) injection model, we tested the effects of RUNX1 inhibition on neovascular formation. Retinas from mice were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in Data-Independent Acquisition (DIA) mode. In vitro experiments were conducted to assess the effects of von Willebrand factor (vWF) on the migration and sprouting of RUNX1 overexpression endothelial cells (RUNX1-OE). Results: In total, 465 differentially expressed proteins (DEPs) were identified, comprising 295 up-regulated proteins and 170 down-regulated proteins. The bioinformatic analysis revealed significant enrichment in pathways critical to retinal angiogenesis, including extracellular matrix (ECM)-receptor interaction, focal adhesion, and actin cytoskeleton regulation. Following RUNX1 inhibition, we identified 57 overlapping DEPs whose dysregulation was reversed. These rescued proteins showed strong enrichment in ECM-receptor interaction signaling. Notably, vWF, an endothelial-related marker, was identified as a downstream target protein of RUNX1 and was found to be involved in retinal pathological angiogenesis. Conclusions: Our present findings establish RUNX1 as a promising therapeutic target for retinal pathological angiogenesis, with its effect mediated via the vWF axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.